PATHOMIQ_PRAD analyzes digitized H&E radical proctectomy whole slide images using our AI platform to produce a report which assesses risk of biochemical relapse and risk of metastasis. PATHOMIQ_PRAD has been shown to outperform state-of-the-art genomic tools after multiple validation studies at various medical institutions and large-cap pharmaceuticals.
PATHOMIQ_PRAD Score
Determined by digitized H&E radical proctectomy images, not influenced by clinical metrics (e.g., Gleason, PSA, age, etc.)
State-of-the-art AI models process images.
Continuous risk score
2 risk factors (biochemical relapse, metastasis)
Interpretation
Summary based on the patient’s risk of biochemical relapse, risk of metastasis, and relevant clinical findings
Risk of Biochemical Relapse
Patient is considered to be in the high or low risk group as determined by the PATHOMIQ_PRAD score.
Kaplan Meier survival model shows which stratified subgroup the patient is most similar to when compared to validation cohort.
Risk of Metastasis
Patient is considered to be in the high or low risk group as determined by the PATHOMIQ_PRAD score.
Kaplan Meier survival model shows which stratified subgroup the patient is most similar to when compared to validation cohort.
PATHOMIQ_PRAD has been validated in multiple settings.
Patients determined to be intermediate risk were stratified into PATHOMIQ_PRAD High and PATHOMIQ_PRAD low, identifying high risk patients who may have previously been overlooked. Read more about this study.
The PATHOMIQ_PRAD score was used to identify patients at highest risk of metastatic progression in the non-metastatic castration resistant prostate cancer setting in the SPARTAN clinical trial. A high score is also indicative of much better response to anti-androgen apalutamide treatment. Read more about this study.
Not only do we provide a logistical benefit when compared to genomic tests, we also outperform them. Read more about this study.